Navarese EP,Robinson JG,Kowalewski M,Kolodziejczak M,Andreotti F,Bliden K .2018 .Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: A systematic review and meta-analysis. JAMA, 2525(15) : 1566-79.
Collaboration CTT,Fulcher J,O'Connell R,Voysey M,Emberson J,Blackwell L .2015 .E cacy and safety of LDLlowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet, 6736(14) : 61368-4.
Abifadel M,Varret M,Rabes JP,Allard D,Ouguerram K,Devillers M .2003 .Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet, 10(2) : 154-6.
Denis M,Marcinkiewicz J,Zaid A,Gauthier D,Poirier S,Lazure C .2012 .Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation, 10(7) : 894-901.
Ference BA,Robinson JG,Brook RD,Catapano AL,Chapman MJ,Ne DR .2016 .Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med, 10(22) : 2144-53.
de Carvalho LSF,Campos AM,Sposito AC .2018 .Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: A systematic review and metaanalysis with over 96,000 patient-years. Diabetes Care, 10(2) : 1464-7.
Monami M,Sesti G,Mannucci E. .2019 .PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes Obes Metab, 10(4) : 903-8.
Moher D,Liberati A,Tetzla J,Altman DG .2009 .6(7): e1000097. PLoS Med, 1000097 : .
Higgins JP,Altman DG,Gotzsche PC,Juni P,Moher D,Oxman AD .2011 .The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 10 : .
Ray KK,Leiter LA,Wieland DM,Cariou B,Colhoun HM,Henry RR .2018 .Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomised trial. Diabetes Obes Metab, 10(6) : 1479-89.
Burggraaf B,Pouw NMC,Arroyo SF,der Zee LCV,de Geijn GMv,Birnie E .2020 .A placebo-controlled proof-of-concept study of alirocumab on postprandial lipids and vascular elasticity in insulin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab, 10(5) : 807-16.
Rosenson RS,Daviglus ML,Handelsman Y,Pozzilli P,Bays H,Monsalvo MLe .2019 .t a.l E cacy and safety of evolocumab in individuals with type 2 diabetes mellitus: Primary results of the randomised controlled BANTING study. Diabetologia, 10(6) : 948-58.
Han Y,Chen J,Chopra VK,Zhang S,Su G,Ma C .2019 .Alirocumab e cacy and safetyvs. ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand. J Clin Lipidol, 10(1) : 98-108.
Chen Y,Yuan Z,Lu J,Eliaschewitz FG,Lorenzatti AJ,Monsalvo ML .2019 .Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-speci ed analysis of the Chinese population from the BERSON clinical trial. Diabetes Obes Metab, 10(6) : 1464-73.
Schwartz GG,Steg PG,Szarek M,Bhatt DL,Bittner VA,Diaz R .2018 .Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med, 10(22) : 2097-107.
Hao Y,Yang YL,Wang YC,Li J. .2022 .E ect of the early application of evolocumab on blood lipid pro le and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome. Int Heart J, 10(4) : 052-77.
Janik MJ,Urbach DV,van Nieuwenhuizen E,Zhao J,Yellin O,Dinet MTB .2021 .Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomised, placebo-controlled study. Atherosclerosis, 06 : 20-7.
Raal FJ,Kallend D,Ray KK,Turner T,Koenig W,Wright RS .2020 .Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med, 10(16) : 1520-30.
Ray KK,Wright RS,Kallend D,Koenig W,Leiter LA,Raal FJ .2020 .Two ohase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med, 10(16) : 1507-19.
Huo Y,Chen B,Lian Q,Wang S,Liu L,Lu D . .Tafolecimab in Chinese patients with non-familial hypercholes-. , : .
Leiter LA,Wieland DM,Baccara-Dinet MT,Letierce A,Samuel R .2018 .E cacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: A pooled analysis of 10 phase III ODYSSEY clinical trials. Diabet Med, 10(1) : 121-30.
Cao YX,Liu HH,Dong QT,Li S,Li JJ .2018 .E ect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis. Diabetes Obes Metab, 10(6) : 1391-8.
Mansi IA,Chansard M,Lingvay I,Zhang S,Halm EA .2021 .Association of statin therapy initiation with diabetes progression: A retrospective matched-cohort study. JAMA Intern Med, 5714(12) : 1562-74.
Sattar N,Preiss D,Murray HM,Welsh P,Buckley BM,de Craen AJ .2010 .Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet, 6736(09) : 61965-6.
Casula M,Mozzanica F,Scotti L,Tragni E,Pirillo A,Corrao G .2017 .Statin use and risk of new-onset diabetes: A metaanalysis of observational studies. Nutr Metab Cardiovasc Dis, 03(5) : 396-406.
Laakso M,Kuusisto J,Stancakova A,Kuulasmaa T,Pajukanta P,Lusis AJ .2017 .The METSIM study: A resource for studies of metabolic and cardiovascular diseases. J Lipid Res, 10(3) : 481-93.
Nicholls SJ,Puri R,Anderson T,Ballantyne CM,Cho L,Kastelein JJ .2016 .E ect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomised clinical trial. JAMA, 316(22) : 2373-84.
.2016 .. doi: 10, 16951 : .
Da Dalt L,Ruscica M,Bonacina F,Balzarotti G,Dhyani A,Di Cairano E .2019 .PCSK9 de ciency reduces insulin secretion and promotes glucose intolerance: The role of the lowdensity lipoprotein receptor. Eur Heart J, 10(4) : 357-68.
Wong ND,Sattar N. .2023 .Cardiovascular risk in diabetes mellitus: Epidemiology, assessment and prevention. Nat Rev Cardiol, 10(10) : z-95.
Sabatine MS,Giugliano RP,Keech AC,Honarpour N,Wiviott SD,Murphy SA .2017 .Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 10(18) : 1713-22.
Zhang XL,Zhu QQ,Zhu L,Chen JZ,Chen QH,Li GN .2015 .Safety and e cacy of anti-PCSK9 antibodies: A analysis of 25 randomised, controlled trials. BMC Med, 10 : 123.
Blom DJ,Koren MJ,Roth E,Monsalvo ML,Djedjos CS,Nelson P .2017 .Evaluation of the e cacy, safety and glycaemic e ects of evolocumab (AMG 145) in hypercholesterolaemic patients strati ed by glycaemic status and metabolic syndrome. Diabetes Obes Metab, 10(1) : 98-107.
Cariou B,Leiter LA,Wieland DM,Bigot G,Colhoun HM,Prato SD .2017 .E cacy and safety of alirocumab in insulintreated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial. Diabetes Metab, 01(5) : 453-9.
'Donoghue O,Giugliano ML,Wiviott RP,Atar SD,Keech D,Kuder A,JF A .2022 .Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation, 10(15) : 1109-19.
Ballantyne CM,Banka P,Mendez G,Garcia R,Rosenstock J,Rodgers A .2023 .Phase 2b randomised trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol, 02(16) : 1553-64.
Patel RS,Scopelliti EM,Olugbile O. .2018 .The role of PCSK9 inhibitors in the treatment of hypercholesterolemia. Ann Pharmacother, 10(10) : 1000-18.